Mannitol-induced Release of Copeptin in Healthy Adults and Patients With Polyuria-Polydipsia Syndrome (MARS Study)

NACompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 10, 2024

Primary Completion Date

July 22, 2025

Study Completion Date

July 22, 2025

Conditions
Polyuria-polydipsia SyndromeArginine Vasopressin DeficiencyPrimary Polydipsia
Interventions
DIAGNOSTIC_TEST

Mannitol Infusion (blinded)

1 g of mannitol per kg body weight is infused in 30 minutes (≙ 5 ml/kg body weight), with an upper limit of 80 g, equivalent to a body weight of 80 kg or a volume of 400 ml. The solution used for infusion is 20% mannitol in water for injection and is administered at a rate of 0.17 ml/kg/min.

DIAGNOSTIC_TEST

Placebo Infusion (blinded)

0.9% saline will be administered in the same amount as the mannitol dose infusion (= 5 ml/kg body weight), with a rate of 0.17 ml/kg/min in 30 minutes, with an upper limit of 400 ml (equivalent to a body weight of 80 kg).

DIAGNOSTIC_TEST

Mannitol Infusion (open label)

1 g of mannitol per kg body weight is infused in 30 minutes (≙ 5 ml/kg body weight), with an upper limit of 80 g, equivalent to a body weight of 80 kg or a volume of 400 ml. The solution used for infusion is 20% mannitol in water for injection and is administered at a rate of 0.17 ml/kg/min.

Trial Locations (1)

4031

University Hospital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT06542198 - Mannitol-induced Release of Copeptin in Healthy Adults and Patients With Polyuria-Polydipsia Syndrome (MARS Study) | Biotech Hunter | Biotech Hunter